Oral Session 3-7A Multiple Myeloma: Daratumumab

[OS3-7A-1] Daratumumab/len/dex (D-Rd) in transplant-ineligible (TIE) NDMM: MMY1006 (Japanese patients) and MAIA

Kenshi Suzuki¹, Shinsuke Iida², Hirohiko Shibayama³, Thierry Facon⁴, Nizar Bahlis⁵, Saad Z Usmani⁶, Hiroshi Yamazaki⁷, Hiromi Koga⁷, Akiko Suzuki⁷, Jianping Wang⁸, Rian Van Rampelbergh⁹, Hiroyuki Takamatsu¹⁰ (1.Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan, 2.Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 3.Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan, 4.Service des Maladies du Sang, Hopital Claude Huriez, Lille, France Metropolitan, 5.University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, Alberta, Canada, 6.Levine Cancer Institute/Atrium Health, Charlotte, NC, United States of America, 7.Janssen Pharmaceutical K.K., Research & Development Division, Tokyo, Japan, 8.Janssen Research & Development, Raritan, NJ, United States of America, 9.Janssen Research & Development, Beerse, Kingdom of Belgium, 10.Hematology/Respiratory Medicine, Kanazawa University, Kanazawa, Japan)